CRE Delinquencies Are Rising. The Grid Can't Keep Up With AI. And Big Pharma Is Panic-Buying. Three Pressure Points.
A quick note from Behind the Markets
Wall Street is doing that thing again. They're arguing about the S&P like it's the whole economy.
Meanwhile, the real pressure is building in places that don't trend on FinTwit: commercial real estate rollover risk, the physical power constraint behind the AI boom, and a biotech M&A wave that screams "patent cliff panic."
Let's talk about the real market.
1) CRE Delinquency Is Rising — and the Real Risk Is the Refinancing Math, Not the Headline Default Rate
Most retail investors hear "CRE trouble" and think it's old news. It's not.
The Mortgage Bankers Association reported overall commercial mortgage delinquency rates rose to 4.02% in Q1 2026, up from 3.86% the prior quarter. CMBS delinquency climbed to 5.21%, up from 4.97%. But those are the polite numbers.
Trepp's separate reading puts the U.S. CMBS delinquency rate at 7.55% in March 2026, with office CMBS hitting an all-time high of 12.34% in January. CRED iQ's March 2026 data shows a CMBS distress rate — including both delinquent and specially serviced loans — of approximately 12%. And GSE-backed loans saw delinquencies jump from 0.63% to 0.97% in a single quarter, while FHA multifamily and healthcare loans climbed from 0.65% to 0.96%.
MBA flagged a critical detail: early-stage delinquency jumps across GSE, FHA, and CMBS loans suggest the "fix-it" toolbox — refinances, modifications, extensions — was more effective in 2025 than it is now. The tools are running out.
Here's the kill math. The average interest rate on CRE loans issued this year is 6.24%. The average rate on the older debt coming due is 4.76%. That 148 basis point gap is the refinancing spread that turns performing loans into problem loans — not because the building stopped producing income, but because the debt service jumped 30% overnight. And $875 billion in commercial and multifamily mortgage debt matures this year.
This isn't just office. MBA highlighted larger early-stage increases from multifamily, office, and healthcare properties. The slow spread beyond office is the signal most investors are missing.
One ETF to track whether CRE stress is contained or spreading into the broader lending environment:
ETF: SPDR S&P Regional Banking ETF (SYM: KRE)
The real-time gauge of credit health at the banks most concentrated in CRE lending and most exposed to the $875 billion maturity wall.
Regional and community banks hold a disproportionate share of CRE loans — in many cases, CRE represents 200–300% of risk-based capital. When delinquencies tick up, these banks don't blow up. They quietly stop lending. And when the marginal lender pulls back, the economy slows without a headline crash. KRE tells you whether that tightening is happening — through deposit trends, NIM compression, and provision builds — before the official narrative catches up.
Bottom line: CRE is a refinancing problem wearing a delinquency mask. The market will ignore it until credit terms tighten — and then it will pretend it "came out of nowhere."
American Alternative Assets
The move Washington made in 1934
In 1934, the government executed a legal maneuver that transferred billions in wealth overnight.
Most Americans had no idea it was coming.
A small group who saw it early walked away wealthy.
Everyone else paid for it.
Trump has the same legal authority today. Advisors close to the administration believe he's considering using it. If he does, the transfer happens fast — and the window to be on the right side of it is already closing.
We put together a free report on exactly what this move is, why the timing points to now, and the one step ordinary Americans can take to position themselves before it happens.
It costs nothing. Takes 30 seconds to request.
The people who moved early in 1934 didn't have a warning.
You do.
2) AI's Biggest Constraint Isn't Chips — It's Power. And Nuclear Is Creeping Back Into the Conversation.
Wall Street wants to sell you the AI boom as a software story. In reality, it's becoming an energy story.
The World Economic Forum highlighted IEA analysis projecting data center electricity consumption rising from 415 TWh in 2024 to 945 TWh by 2030 — more than doubling in six years. That's not a theoretical projection. The $1.4 trillion utility buildout, the NERC load growth revision from 6.1% to 11.6% over the next decade, and the hyperscalers committing $635–$700 billion in capex this year all confirm the demand is real and accelerating.
"Speed to power" is becoming the new "speed to market." The winners aren't the flashiest AI apps. They're the operators who can secure megawatts.
Nuclear is moving from taboo to tool. WEF argues nuclear offers round-the-clock dispatchable power with less exposure to fuel delivery risk because refueling cycles are 18–24 months and fuel can be stored on-site. In a world where the Strait of Hormuz has cut 20% of global LNG supply and Brent is above $110, the ability to generate power without depending on international shipping lanes has moved from "nice to have" to "strategic necessity."
The World Nuclear Association projects installed capacity nearly doubling to 746 GWe by 2040, with uranium consumption rising from roughly 68,900 metric tons this year to more than 150,000 metric tons by 2040. The U.S. has pledged $80 billion for new AP1000 reactors. The DOE committed $2.7 billion for domestic enrichment. And the IEA forecasts annual nuclear investment rising from $70 billion today to $210 billion by 2035.
One company positioned at the intersection of AI power demand and nuclear fuel:
Company: Cameco Corporation (SYM: CCJ)
The world's second-largest uranium producer, operating in the highest-grade deposits on earth, with a joint venture in Westinghouse nuclear fuel manufacturing.
Cameco is currently trading around $121.14. The company's stock was up roughly 70% earlier this year while spot uranium was flat — the equity market pricing in what the commodity market hasn't. Cameco's McArthur River mine produces the highest-grade uranium on the planet. Its long-term contracts lock in prices above spot. And the Westinghouse partnership gives it exposure to the entire nuclear fuel cycle. When AI's power demand collides with a world where Middle Eastern energy supply is structurally unreliable, Cameco sits at the intersection of every driver.
Bottom line: AI is colliding with physics. When electricity becomes the bottleneck, market leadership shifts from "who has the best model" to "who has the power."
3) Big Pharma Is Buying Again — Not Because Biotech Is "Hot," but Because Patents Are a Ticking Clock
The easiest way to tell when a sector is under stress is to watch the buyers. When the giants start shopping, it's usually not optimism. It's urgency.
Reuters reported biotech dealmaking is on pace for a historic 2026, with Q1 biotech M&A value at $84 billion — nearly double Q1 2025's $44.4 billion. Stifel projects 2026 biopharma M&A could exceed $250 billion if momentum holds.
The driver is simple: the patent cliff.
Merck's Keytruda — the world's best-selling drug — loses patent protection in 2028. Across the industry, more than $300 billion in annual revenue is at risk over the next five years from expiring patents across 69+ blockbusters. Big Pharma is sitting on roughly $1 trillion in cash reserves earmarked for dealmaking.
When companies would rather buy than build, it tells you internal R&D timelines can't match the market's demand for growth. That's not bullish sentiment driving acquisitions. That's the clock running out.
Here's the contrarian retail setup: don't chase the acquirers after the press release. Build a basket of "plausible targets" with real fundamentals — clean balance sheets, late-stage assets, clear trial timelines, and a management team that can negotiate.
One ETF that captures the biotech M&A wave without single-name binary risk:
ETF: SPDR S&P Biotech ETF (SYM: XBI)
Equal-weighted biotech exposure across dozens of small and mid-cap names — the acquisition targets and catalyst plays that benefit from the patent-cliff panic.
XBI's equal-weight structure spreads the risk. When M&A premiums hit — and they've been running 40–60% above pre-announcement prices in recent deals — the equal weighting means every target in the portfolio contributes proportionally. When a single approval disappoints, the damage is contained. XBI is the instrument for investors who believe the thesis (patent cliff, $1T cash pile, 20+ deals expected) without wanting to bet their account on a single drug's review date.
Bottom line: This isn't a "biotech bull market." It's a patent-cliff panic. Retail can still win — but only by being systematic and early, not emotional and late.
4) The Market's Next Surprise Won't Be a Crash — It'll Be a Credit Event Nobody Rings a Bell For
Here's how the game usually plays out. First, denial. Then, one "isolated" blow-up. Then, suddenly it's "contagion."
CRE rollover stress at 4.02% overall (12%+ in CMBS distress) plus higher-for-longer rates at 3.50–3.75% plus AI capex competing for real-world resources — power, materials, labor, capital — is not a clean environment. It's a fragile one.
Marathon Asset Management's CEO just warned of a 15% default rate in private credit software portfolios, sustained for two consecutive years, with recovery rates as low as $0–$0.30 on the dollar. The overall U.S. private credit default rate already hit a record 9.2% last year. And Blackstone's non-traded credit vehicle saw record 7.9% redemptions in a single quarter.
Into this morning, ask one question about every stock you own: if credit tightens for six months, does this business get stronger or does it get exposed?
One company built for a world where credit stress creates opportunity:
Company: Berkshire Hathaway (SYM: BRK.B)
Warren Buffett's conglomerate — sitting on $330+ billion in cash, diversified across insurance, energy, railroads, and manufacturing, with the capital and temperament to be the buyer of last resort when credit markets seize.
When CRE stress accelerates, private credit blows up, and regional banks pull back — Berkshire sits on the other side of the table. In 2008, Buffett deployed capital into Goldman, GE, and Bank of America on terms that only unlimited liquidity could demand. If the maturity walls hit in 2027–2028 as Marathon's Richards forecasts, Berkshire is one of the few entities in the world positioned to buy what others are forced to sell.
Bottom line: In this tape, survival is alpha. If a company needs perfect credit markets to look good, it's not a stock — it's a hostage situation.
Before You Go
Wall Street will keep pitching "soft landing" like it's a product.
But if CRE stress keeps creeping higher and AI keeps pulling capital toward power and infrastructure… where do you think the marginal dollar of liquidity goes?
Found this helpful? Share it with others.
Written by Behind the Markets